By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



10732 Hawk’s Vista Street

Plantation  Florida  33324  U.S.A.
Phone: n/a Fax: n/a


Start Up

Company News
Neurotrope To Release Results From Phase II Clinical Trial In Moderate To Severe Alzheimer’s Disease On May 1, 2017 4/28/2017 9:04:37 AM
Neurotrope Announces Approval For Listing On The NASDAQ Capital Market 3/27/2017 8:36:34 AM
Neurotrope Concludes Patient Dosing And Monitoring In Its 148 Patient Phase II Clinical Trial Of Moderate To Severe Alzheimer's Dementia 2/28/2017 6:48:28 AM
Neurotrope Completes Licensing Agreement For Accelerated Synthesis Of Alzheimer's Drug Bryostatin-1 1/30/2017 6:46:03 AM
Neurotrope Release: Biotech Announces Reverse Split Of Common Stock In Preparation For NASDAQ Uplisting 1/12/2017 6:45:41 AM
Neurotrope Issues Statement On Eli Lilly (LLY)'s Solanezumab 11/23/2016 9:04:45 AM
Neurotrope Completes Enrollment In Its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial Of Bryostatin In Patients With Moderate To Severe Alzheimer's Disease 11/22/2016 7:54:20 AM
Neurotrope Announces Private Placement of $20 Million 11/18/2016 7:30:51 AM
Dr. Daniel Alkon Appointed President Of Neurotrope 9/28/2016 7:24:08 AM
Neurotrope Names a New CEO 9/6/2016 6:52:32 AM